Cartesian Therapeutics (RNAC) EBT Margin (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly EBT Margin of 34156.41% for Q1 2026, down 3232086.0% year-over-year from N/an in Q1 2025, and down 312.02% quarter-over-quarter from 8289.97% in Q4 2025.
Cartesian Therapeutics (RNAC) EBT Margin (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported EBT Margin for 12 consecutive years, with 34156.41% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin fell 3232086.0% year-over-year to 34156.41%; the TTM figure through Mar 2026 stood at 16277.07% (down 1599731.0% YoY), while the FY2025 annual figure was 4987.31%, down 478577.0% from the prior year.
- EBT Margin fell to 34156.41% in Q1 2026 per RNAC's latest filing, from 8289.97% in the prior quarter.
- Across five years, EBT Margin topped out at 3024.88% in Q4 2024 and bottomed at 34156.41% in Q1 2026.
- Historically, EBT Margin has averaged 3204.46% across 5 years, with a median of 230.19% in 2023.
- Annual changes were most pronounced in 2024 — EBT Margin jumped 540400 bps — and 2026, when it tumbled 3232086 bps.
- Cartesian Therapeutics' EBT Margin stood at 33.37% in 2022, then plunged by 7229 bps to 2379.12% in 2023, then surged by 227 bps to 3024.88% in 2024, then slumped by 374 bps to 8289.97% in 2025, then sank by 312 bps to 34156.41% in 2026.
- Business Quant data shows RNAC's EBT Margin at 34156.41% in Q1 2026, 8289.97% in Q4 2025, and 1835.55% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Cartesian Therapeutics | 265.54 Mn | 265.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34,156.41% |
| Dec 31, 2025 | -8,289.97% |
| Mar 31, 2025 | -1,835.55% |
| Dec 31, 2024 | 3,024.88% |
| Jun 30, 2024 | -54.49% |
| Mar 31, 2024 | -425.94% |
| Dec 31, 2023 | -2,379.12% |
| Sep 30, 2023 | -137.41% |
| Jun 30, 2023 | -342.85% |
| Mar 31, 2023 | -322.97% |
| Dec 31, 2022 | 33.37% |
| Sep 30, 2022 | -39.66% |
| Jun 30, 2022 | 34.00% |
| Mar 31, 2022 | 29.65% |
| Dec 31, 2021 | 41.34% |
| Sep 30, 2021 | -8.46% |
| Jun 30, 2021 | -1.31% |
| Mar 31, 2021 | -71.22% |
| Dec 31, 2020 | -129.24% |
| Sep 30, 2020 | -209.41% |